Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 474

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Open access
Topp, Max S., Gökbuget, Nicola, Zugmaier, Gerhard, Degenhard, Evelyn, Goebeler, Marie-Elisabeth, Klinger, Matthias, Neumann, Svenja A., Horst, Heinz A., Raff, Thorsten, Viardot, Andreas, Stelljes, Matthias, Schaich, Markus, Köhne-Volland, Rudolf, Brüggemann, Monika, Ottmann, Oliver G., Burmeister, Thomas, Baeuerle, Patrick A., Nagorsen, Dirk, Schmidt, Margit, Einsele, Hermann, Riethmüller, Gert, Kneba, Michael, Hoelzer, Dieter, Kufer, Peter, Bargou, Ralf C.·2012·Blood
DOI 10.1182/blood-2012-07-441030
Open this paper in CoChat — free account

Abstract

Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL). In a phase 2 trial of B-lineage ALL patients with persistent or relapsed MRD, a T cell–engaging bispecific Ab construct induced an 80% MRD response rate. In the present study, we show that after a median follow-up of 33 months, the hematologic relapse-free survival of the entire evaluable study cohort of 20 patients was 61% (Kaplan-Meier estimate). The hema-tologic relapse-free survival rate of a subgroup of 9 patients who received allogeneic hematopoietic stem cell transplantation after blinatumomab treatment was 65% (Kaplan-Meier estimate). Of the subgroup of 6 Philadelphia chromosome–negative MRD responders with no further therapy after blinatumomab, 4 are in ongoing hematologic and molecular remission. We conclude that blinatumomab can induce long-lasting complete remission in B-lineage ALL patients with persistent or recurrent MRD. The original study and this follow-up study are registered at www.clinicaltrials.gov as NCT00198991 and NCT00198978, respectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-07-441030

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 474

Metadata

Authors
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., Stelljes, M., Schaich, M., Köhne-Volland, R., Brüggemann, M., Ottmann, O. G., Burmeister, T., Baeuerle, P. A., Nagorsen, D., Schmidt, M., Einsele, H., Riethmüller, G., Kneba, M., Hoelzer, D., Kufer, P., & Bargou, R. C.
Venue
Blood
Publisher
American Society of Hematology
Published
2012-12-20
Volume
120
Issue
26
Pages
5185-5187
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2012-07-441030
OpenAlex
W2038414910
Cited by
474
References
3
FWCI
54.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. https://app.cochat.ai/papers/10.1182/blood-2012-07-441030
The paper
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., Stelljes, M., Schaich, M., Köhne-Volland, R., Brüggemann, M., Ottmann, O. G., Burmeister, T., Baeuerle, P. A., Nagorsen, D., Schmidt, M., . . . Bargou, R. C. (2012). Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. https://doi.org/10.1182/blood-2012-07-441030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.